Catalyst Watch – Vol. 3, Edition 9 (7/8/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 8 (5/28/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 7 (5/15/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 6 (4/30/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 5 (4/17/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 4 (4/3/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 3 (3/18/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 2 (3/6/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 3 (1/18/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 2 (1/27/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 3, Edition 1 (1/15/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 36 (12/30/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 35 (12/11/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 34 (12/5/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 33 (11/20/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 32 (11/5/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 31 (10/23/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

MRK – A Falling Knife Or a Golden Opportunity

  Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach.

Catalyst Watch – Vol. 2, Edition 30 (10/14/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

CNAT – A Quick Chart Update

  Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.

Catalyst Watch – Vol. 2, Edition 29 (10/2/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 28 (9/26/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 27 (9/19/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Recent Option Activity (9/10 ~ 9/11)

The following stocks had recent and notable activity in their options: $MRK (9/10): 12,800 JAN15 50.0 strike Calls were sold (stock at $60.56) for 10.70 or total proceeds of $13.7.

Catalyst Watch – Vol. 2, Edition 26 (9/9/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 25 (8/26/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Recent Option Activity (8/6 ~ 8/12)

The following stocks had recent and notable activity in their options: $INFI (8/6): 3,822 SEP 10.0 strike Puts were sold (stock at $9.98) for 0.45 or total proceeds of $171,990..

Catalyst Watch – Vol. 2, Edition 24 (8/11/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Recent Option Activity (7/29 ~ 8/1)

The following stocks had recent and notable activity in their options: $EXAS (7/29): 8,000 OCT 20.0 Strike Calls were sold (stock at $15.78) for 0.50 or total proceeds of $400,000.

Catalyst Watch – Vol. 2, Edition 23 (7/29/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 22 (7/7/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Browsing 31 / 192 articles